(ARQT) –
-
Form 4 Arcutis Biotherapeutics, For: Apr 10 Filed by: Topper David Joseph
-
Form 3 Arcutis Biotherapeutics, For: Apr 10 Filed by: Topper David Joseph
-
Form 8-K Arcutis Biotherapeutics, For: Apr 10
-
Arcutis Biotherapeutics (ARQT) Appoints David Topper as Chief Financial Officer
-
Arcutis Appoints David Topper as Chief Financial Officer
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sol-Gel Technologies (SLGL) Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve Cream
-
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
-
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
-
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
-
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
-
Form 4 Arcutis Biotherapeutics, For: Mar 04 Filed by: Matsuda Masaru
-
Form 4 Arcutis Biotherapeutics, For: Mar 04 Filed by: Burnett Patrick
-
Form 4 Arcutis Biotherapeutics, For: Mar 04 Filed by: Watanabe Todd Franklin
-
Form 4 Arcutis Biotherapeutics, For: Mar 04 Filed by: Moore Matthew Richard
-
Form 4 Arcutis Biotherapeutics, For: Mar 04 Filed by: Heron Patrick J
-
Form SC 13D/A Arcutis Biotherapeutics, Filed by: Frazier Life Sciences VIII, L.P.
-
Form SC 13G/A Arcutis Biotherapeutics, Filed by: JENNISON ASSOCIATES LLC
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Form 144 Arcutis Biotherapeutics, Filed by: Watanabe Todd Franklin
-
Form 144 Arcutis Biotherapeutics, Filed by: OSBORNE DAVID W
-
Form 144 Arcutis Biotherapeutics, Filed by: Moore Matthew Richard
-
Form 144 Arcutis Biotherapeutics, Filed by: Matsuda Masaru
-
Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick
-
Form 8-K Arcutis Biotherapeutics, For: Feb 28
-
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
-
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
-
Form 4 Arcutis Biotherapeutics, For: Feb 28 Filed by: Watanabe Todd Franklin
-
Form 424B5 Arcutis Biotherapeutics,
-
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
-
Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Morgan Stanley
-
Arcutis Biotherapeutics (ARQT) Announces Pricing of $150 Mln Public Offering
-
Arcutis Announces Pricing of $150 Million Public Offering
-
Form 144 Arcutis Biotherapeutics, Filed by: Watanabe Todd Franklin
-
Form 424B5 Arcutis Biotherapeutics,
-
Form 8-K Arcutis Biotherapeutics, For: Feb 27
-
Arcutis Biotherapeutics (ARQT) Announces Proposed $150M Share Offering
-
Arcutis Announces Proposed Public Offering
-
Arcutis Biotherapeutics (ARQT) and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
-
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
-
Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $16 at Needham
-
Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $17 at Mizuho
-
Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $11 at Goldman Sachs, 'Zoryve launches trending positively'
-
Form S-8 Arcutis Biotherapeutics,
-
Form 10-K Arcutis Biotherapeutics, For: Dec 31
-
Form 8-K Arcutis Biotherapeutics, For: Feb 27
-
Arcutis Biotherapeutics, Inc. (ARQT) Tops Q4 EPS by 6c
-
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $16 at Mizuho Securities
Back to ARQT Stock Lookup
